Oklahoma AG sues distributors of opioids
Oklahoma Attorney General Mike Hunter on Monday brought a lawsuit against three distributors of opioids after winning a lawsuit against one drug manufacturer and reaching pretrial settlements in other cases.
Hunter filed the lawsuit in Cleveland County District Court against Cardinal Health, McKesson Corp. and AmerisourceBergen Corp.
“Oklahoma is in crisis . ... The source of this crisis is the flood of prescription opioids that has inundated Oklahoma for the past two decades,” the lawsuit says. “It is a man-made crisis. It was brought into being by the pharmaceutical industry.”
The lawsuit said the defendants “distributed what can only be called a major oversupply of opioids into Oklahoma.”
Hunter’s spokesman, Alex Gerszewski, said the companies distributed opioids primarily to hospitals and pharmacies and were obligated to have a systems of checks and balances to alert them if there was a sharp, unexplained increase in opioid orders.
“They’re supposed to take that as a red flag” and notify law enforcement, Gerszewki said.
“Any suggestion that McKesson drove demand for opioids in this country reflects a fundamental misunderstanding and mischaracterization of our role as a distributor,” McKesson said in a statement Monday.
Cardinal Health and AmerisourceBergen Drug Corp. did not immediately respond to a request for comment.
The suit comes after Hunter won a lawsuit in August against opioid manufacturer Johnson & Johnson, which was ordered to pay $465 million.
Both Hunter and Johnson & Johnson have appealed the ruling.
Hunter’s office says the award is only enough to pay for one year of the state’s opioid abatement plan. Johnson & Johnson maintains the award should be reduced by $355 million to offset pretrial settlements reached with other drugmakers.
The state reached settlements last year of $270 million with drugmaker Purdue Pharma and $85 million with Israeli-owned Teva Pharmaceuticals.
An $8.75 million settlement was reached last week with Endo Pharmaceuticals Inc. and Par Pharmaceutical, Inc., both subsidiaries of Dublinbased Endo International.